Cargando…

The burden of colorectal cancer survivors in the Netherlands: costs, utilities, and associated patient characteristics

PURPOSE: The aim of this study is to assess the societal burden of colorectal cancer (CRC) survivorship 2–10 years post-diagnosis in terms of (1) societal costs, and (2) quality of life/utilities, and to analyze associated patient characteristics. METHODS: This is a cross-sectional, bottom-up preval...

Descripción completa

Detalles Bibliográficos
Autores principales: Mulder, Frederike E. C. M., van Roekel, Eline H., Bours, Martijn J. L., Weijenberg, Matty P., Evers, Silvia M. A. A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9489543/
https://www.ncbi.nlm.nih.gov/pubmed/34510364
http://dx.doi.org/10.1007/s11764-021-01096-6
_version_ 1784792905799434240
author Mulder, Frederike E. C. M.
van Roekel, Eline H.
Bours, Martijn J. L.
Weijenberg, Matty P.
Evers, Silvia M. A. A.
author_facet Mulder, Frederike E. C. M.
van Roekel, Eline H.
Bours, Martijn J. L.
Weijenberg, Matty P.
Evers, Silvia M. A. A.
author_sort Mulder, Frederike E. C. M.
collection PubMed
description PURPOSE: The aim of this study is to assess the societal burden of colorectal cancer (CRC) survivorship 2–10 years post-diagnosis in terms of (1) societal costs, and (2) quality of life/utilities, and to analyze associated patient characteristics. METHODS: This is a cross-sectional, bottom-up prevalence-based burden of disease study, conducted from a societal perspective in the Netherlands. In total, 155 CRC survivors were included. Utilities were measured by the EQ-5D-5L, using the Dutch tariffs. A cost questionnaire was developed to obtain cost information. Subgroup analyses were performed, based on patient characteristics and sensitivity analyses. RESULTS: Of all CRC survivors, 81(54%) reported no problems for mobility, 133(88%) for self-care, 98(65%) for daily activities, 59(39%) for pain/discomfort, and 112(74%) for anxiety/depression on the EQ-5D-5L. The average EQ-5D-5L utility score was 0.82 (SD = 0.2) on a scale from 0 (death) to 1 (perfect health). Significant differences in utility score were found for gender, tumor stage, number of comorbidities, and lifestyle score. The average societal costs per CRC survivor per 6 months were estimated at €971 (min = €0, max = €32,425). Significant differences in costs were found for the number of comorbidities. CONCLUSIONS: This study shows a considerable burden of CRC survivors 2–10 years after diagnosis, in comparison with survivors sooner after diagnosis and with healthy individuals in the Netherlands. IMPLICATIONS FOR CANCER SURVIVORS: Long-term care of CRC survivors should focus on improving the societal burden by identifying modifiable factors, as summarized in the WCRF/AICR lifestyle score, including body composition, physical activity, and diet.
format Online
Article
Text
id pubmed-9489543
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-94895432022-09-22 The burden of colorectal cancer survivors in the Netherlands: costs, utilities, and associated patient characteristics Mulder, Frederike E. C. M. van Roekel, Eline H. Bours, Martijn J. L. Weijenberg, Matty P. Evers, Silvia M. A. A. J Cancer Surviv Article PURPOSE: The aim of this study is to assess the societal burden of colorectal cancer (CRC) survivorship 2–10 years post-diagnosis in terms of (1) societal costs, and (2) quality of life/utilities, and to analyze associated patient characteristics. METHODS: This is a cross-sectional, bottom-up prevalence-based burden of disease study, conducted from a societal perspective in the Netherlands. In total, 155 CRC survivors were included. Utilities were measured by the EQ-5D-5L, using the Dutch tariffs. A cost questionnaire was developed to obtain cost information. Subgroup analyses were performed, based on patient characteristics and sensitivity analyses. RESULTS: Of all CRC survivors, 81(54%) reported no problems for mobility, 133(88%) for self-care, 98(65%) for daily activities, 59(39%) for pain/discomfort, and 112(74%) for anxiety/depression on the EQ-5D-5L. The average EQ-5D-5L utility score was 0.82 (SD = 0.2) on a scale from 0 (death) to 1 (perfect health). Significant differences in utility score were found for gender, tumor stage, number of comorbidities, and lifestyle score. The average societal costs per CRC survivor per 6 months were estimated at €971 (min = €0, max = €32,425). Significant differences in costs were found for the number of comorbidities. CONCLUSIONS: This study shows a considerable burden of CRC survivors 2–10 years after diagnosis, in comparison with survivors sooner after diagnosis and with healthy individuals in the Netherlands. IMPLICATIONS FOR CANCER SURVIVORS: Long-term care of CRC survivors should focus on improving the societal burden by identifying modifiable factors, as summarized in the WCRF/AICR lifestyle score, including body composition, physical activity, and diet. Springer US 2021-09-11 2022 /pmc/articles/PMC9489543/ /pubmed/34510364 http://dx.doi.org/10.1007/s11764-021-01096-6 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Mulder, Frederike E. C. M.
van Roekel, Eline H.
Bours, Martijn J. L.
Weijenberg, Matty P.
Evers, Silvia M. A. A.
The burden of colorectal cancer survivors in the Netherlands: costs, utilities, and associated patient characteristics
title The burden of colorectal cancer survivors in the Netherlands: costs, utilities, and associated patient characteristics
title_full The burden of colorectal cancer survivors in the Netherlands: costs, utilities, and associated patient characteristics
title_fullStr The burden of colorectal cancer survivors in the Netherlands: costs, utilities, and associated patient characteristics
title_full_unstemmed The burden of colorectal cancer survivors in the Netherlands: costs, utilities, and associated patient characteristics
title_short The burden of colorectal cancer survivors in the Netherlands: costs, utilities, and associated patient characteristics
title_sort burden of colorectal cancer survivors in the netherlands: costs, utilities, and associated patient characteristics
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9489543/
https://www.ncbi.nlm.nih.gov/pubmed/34510364
http://dx.doi.org/10.1007/s11764-021-01096-6
work_keys_str_mv AT mulderfrederikeecm theburdenofcolorectalcancersurvivorsinthenetherlandscostsutilitiesandassociatedpatientcharacteristics
AT vanroekelelineh theburdenofcolorectalcancersurvivorsinthenetherlandscostsutilitiesandassociatedpatientcharacteristics
AT boursmartijnjl theburdenofcolorectalcancersurvivorsinthenetherlandscostsutilitiesandassociatedpatientcharacteristics
AT weijenbergmattyp theburdenofcolorectalcancersurvivorsinthenetherlandscostsutilitiesandassociatedpatientcharacteristics
AT everssilviamaa theburdenofcolorectalcancersurvivorsinthenetherlandscostsutilitiesandassociatedpatientcharacteristics
AT mulderfrederikeecm burdenofcolorectalcancersurvivorsinthenetherlandscostsutilitiesandassociatedpatientcharacteristics
AT vanroekelelineh burdenofcolorectalcancersurvivorsinthenetherlandscostsutilitiesandassociatedpatientcharacteristics
AT boursmartijnjl burdenofcolorectalcancersurvivorsinthenetherlandscostsutilitiesandassociatedpatientcharacteristics
AT weijenbergmattyp burdenofcolorectalcancersurvivorsinthenetherlandscostsutilitiesandassociatedpatientcharacteristics
AT everssilviamaa burdenofcolorectalcancersurvivorsinthenetherlandscostsutilitiesandassociatedpatientcharacteristics